Announcement on Obtaining Drug Registration Approval by the Wholly-owned Subsidiary
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Filed with SSE · · 2 pages · Chinese
Aurisco Pharmaceutical Co. Ltd. announced that its wholly-owned subsidiary has received drug registration approval for a new product. The approved product is a combination of estradiol and dydrogesterone tablets, intended for treating menopausal symptoms. This approval is expected to enhance the company's market competitiveness and positively impact its financial performance. The company emphasizes the importance of quality control in drug development and manufacturing processes.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
On 6ix: 6ix.com/news/announcement-on-obtaining-drug-registration-approval-by-the-wholly-owned-subsidiary
Announcement on Obtaining Drug Registration Approval by the Wholly-owned Subsidiary
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Aurisco Pharmaceutical Co. Ltd. on 6ix
Follow Aurisco Pharmaceutical into a list and get an email when it puts out news.
Follow Aurisco Pharmaceutical